THE VALUED VOICE

Physician Edition

Tuesday, April 19, 2022

   

Buprenorphine X-Waiver Training Webinars Offered

Registration is open for buprenorphine x-waiver training webinars sponsored by the Wisconsin Society of Addiction Medicine and the Wisconsin Department of Health Services.
 
These webinars are part of an effort to expand the prescribing of buprenorphine, a medication used to treat opioid use disorder. The courses are open to MDs, DOs, NPs and PAs. Registration is required. There is no registration fee for the webinars. The American Society of Addiction Medicine's four-hour on-demand training course must be completed prior to attending any of the live virtual trainings listed below. 
   Visit the Wisconsin Society of Addiction Medicine's website for more information on these webinars.
 
Visit the Wisconsin Department of Health Services’ “Resources for Professionals” webpage for additional resources for prescribers, including additional information about becoming a buprenorphine waivered practitioner to treat opioid use disorder. 
WHA Logo
Tuesday, April 19, 2022

Buprenorphine X-Waiver Training Webinars Offered

Registration is open for buprenorphine x-waiver training webinars sponsored by the Wisconsin Society of Addiction Medicine and the Wisconsin Department of Health Services.
 
These webinars are part of an effort to expand the prescribing of buprenorphine, a medication used to treat opioid use disorder. The courses are open to MDs, DOs, NPs and PAs. Registration is required. There is no registration fee for the webinars. The American Society of Addiction Medicine's four-hour on-demand training course must be completed prior to attending any of the live virtual trainings listed below. 
   Visit the Wisconsin Society of Addiction Medicine's website for more information on these webinars.
 
Visit the Wisconsin Department of Health Services’ “Resources for Professionals” webpage for additional resources for prescribers, including additional information about becoming a buprenorphine waivered practitioner to treat opioid use disorder. 

Other Articles in this Issue